Annovis Bio Achieves Key Milestones in Phase 3 Alzheimer's Trial with All Sites Activated

Annovis Bio Inc. has reached significant milestones in its pivotal Phase 3 clinical trial for early Alzheimer's disease, with all 84 U.S. clinical sites now fully activated and enrolling patients. The late-stage clinical drug platform company announced that most sites are already treating participants, and the first group has completed the 6-month treatment phase, keeping the company on schedule to deliver symptomatic data in the second half of 2026. The study, which is now 25% complete according to company statements, represents a critical step forward in developing treatments for Alzheimer's disease, a condition affecting millions worldwide with limited therapeutic options.

CEO Maria Maccecchini characterized the progress as reflecting strong execution and continued momentum toward bringing the company's lead candidate, buntanetap, to patients in need of effective therapies for neurodegenerative diseases. Annovis Bio's approach to treating Alzheimer's focuses on buntanetap, which the company is developing as part of its broader platform targeting neurodegenerative conditions including both Alzheimer's and Parkinson's diseases. The completion of site activation across all planned locations enables broader patient recruitment and accelerates the trial timeline, potentially bringing new treatment options to market more quickly.

This Phase 3 trial progress comes at a time when the Alzheimer's treatment landscape is evolving rapidly, with recent approvals of new therapies highlighting the urgent need for additional effective options. The successful site activation and patient treatment milestones suggest Annovis Bio is maintaining its development timeline despite the complexities of conducting large-scale neurodegenerative disease trials. The company maintains an online presence where investors and interested parties can access additional information through its official website at https://www.annovisbio.com.

The company's focus on both Alzheimer's and Parkinson's diseases positions it to address multiple major neurodegenerative conditions with its platform technology. As the trial continues enrollment and treatment, the medical community will be watching closely for the symptomatic data expected in 2026, which could provide important insights into buntanetap's potential efficacy in treating early Alzheimer's disease symptoms. For those following the company's stock performance and development updates, the latest news relating to ANVS is available in the company's newsroom at https://ibn.fm/ANVS.